Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

PURPOSE: In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sézary syndrome (SS) is quite variable. Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was eval...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Kim, Youn H., Tavallaee, Mahkam, Sundram, Uma, Salva, Katrin A., Wood, Gary S., Li, Shufeng, Rozati, Sima, Nagpal, Seema, Krathen, Michael, Reddy, Sunil, Hoppe, Richard T., Nguyen-Lin, Annie, Weng, Wen-Kai, Armstrong, Randall, Pulitzer, Melissa, Advani, Ranjana H., Horwitz, Steven M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2015
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089160/
https://ncbi.nlm.nih.gov/pubmed/26195720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.3969
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares